SCHEMBL6042250

SCHEMBL6042250

O=C(O)N1CCC(c2ccccc2)C(O)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.55
HTT P42858 1/20 0.51
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TP53 P04637 2/20 0.47
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 2/20 0.44
SIGMAR1 Q99720 2/20 0.43
BACE1 P56817 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
CHRNA7 P36544 1/20 0.42
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241225 1.00 SLC18A3 (0.55) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL2241229 1.00 SLC18A3 (0.55) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL5779590 0.87 SLC18A3 (0.42) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL4351851 0.87 HTT (0.44) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL5200597 0.87 SLC18A3 (0.47) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL5198776 0.87 SLC18A3 (0.47) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL5198510 0.87 SLC18A3 (0.47) SLC18A3HTTNPC1RAB9ASMN1; SMN2
SCHEMBL23291451 0.86 KDM1A (0.45) SLC18A3HTTALDH1A1POLBHRH3
SCHEMBL6043859 0.86 MAPT (0.45) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL6041675 0.86 KDM1A (0.45) SLC18A3HTTALDH1A1POLBHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 SLC18A3 400/4885HTT 155/4885NPC1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.